Emma Stanton

VP Clinical at Oxford Nanopore Technologies and Head of Oxford Nanopore Diagnostics
Summary
Dr Emma Stanton is a seasoned professional with a diverse background in healthcare, clinical leadership, and organizational management. Currently serving as the VP Clinical at Oxford Nanopore Technologies and Head of Oxford Nanopore Diagnostics, Emma is dedicated to integrating nanopore sequencing into clinical settings to revolutionize healthcare services. Her commitment to healthcare innovation is evident through her extensive experience and achievements in various key roles.
During the critical period of June to November 2020, Emma contributed significantly as the Director for Supplies and Innovation as part of the UK government's NHS Test and Trace response to the COVID-19 pandemic. Prior to her role at Oxford Nanopore, Emma was the CEO of Four Eyes Insight, specializing in enhancing clinical efficiency and driving sustainable improvements in healthcare systems.
Emma's professional journey includes impactful leadership positions at Beacon Health Options, where she served as the Chief Partnership Officer for the Northeast USA, Associate Chief Medical Officer for the organization in the USA, and also founded and led Beacon in the UK. With a strong academic background, Emma's qualifications range from an executive MBA from Imperial College, London, to a Bachelor of Medicine from the University of Southampton.
Having been recognized as one of HSJ's most inspirational women in health and a top innovator in the NHS, Emma's contributions to the healthcare sector are highly regarded. Her expertise extends to various areas such as clinical leadership, healthcare policy, and competitiveness strategies, exemplified by her involvement as a senior associate at the Institute for Strategy and Competitiveness at Harvard Business School.